Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to investigate the effects of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to subsequent illness in children aged 1-15 either with or without acute MeV infection.


Clinical Trial Description

This is a prospective, observational, longitudinal study to be conducted in West Africa. Eligible children will be enrolled into 1 of 2 arms: acute MeV infection (cases) or no acute MeV infection (controls) as assessed using upper respiratory specimens and blood samples. Blood samples will be collected at screening/enrollment (Day 0) and follow-up visits on Day 14, Week 13, and Week 52, and tested for humoral and cellular immune responses to endemic pathogens to determine changes in antibody diversity and antibody secreting cells (ASCs). All children in each arm will receive rabies vaccination (standard 3-dose series given as pre-exposure prophylaxis [PrEP]), with the first dose randomized to either Week 8 or Week 47 after enrollment. Biological samples will be collected after vaccination to assess if the immune stimulus (rabies vaccine) response differs: 1) between children with and without MeV infection, and 2) based on the timing of the receipt of the rabies vaccine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06153979
Study type Observational
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact Karine G Fouth Tchos, M.D., M.Ph.
Phone 240-627-3641
Email karine.fouthtchos@nih.gov
Status Recruiting
Phase
Start date January 16, 2024
Completion date June 2025

See also
  Status Clinical Trial Phase
Recruiting NCT01486355 - Additional Measles Vaccine at 4 Months of Age Phase 4